Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2012
At a glance
- Drugs TAS 106 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 23 Mar 2012 Actual patient number (27) added as reported by ClinicalTrials.gov.
- 23 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 23 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.